Business Context and Reporting Period
Cocrystal Pharma, Inc. (COCP), a biotechnology company incorporated in Delaware, filed this Form 8-K on March 30, 2020. The filing primarily serves to announce the results of operations for the quarter and year ended December 31, 2019, via a press release furnished as Exhibit 99.1. Additionally, the report addresses operational continuity measures taken in response to the COVID-19 pandemic.
Key Financial Metrics
The filing text references a press release containing specific financial results for the period ended December 31, 2019, but does not explicitly state the numerical values for revenue, profit, cash flow, margins, debt, or liquidity within the body of this 8-K document. Investors must refer to the attached Exhibit 99.1 or the previously filed Form 10-K for these specific figures.
Material Changes and Operational Updates
- COVID-19 Response: On March 23, 2020, the Washington State Governor issued a stay-at-home proclamation. Cocrystal Pharma's research laboratory in Bothell, Washington, remains open as it is designated for "Essential Critical Infrastructure Workers" conducting research critical to the COVID-19 response and developing biotechnology therapies.
- Operational Continuity: While the lab remains open for essential operations, scientists are also permitted to work remotely. The company remains committed to meeting its corporate and development milestones throughout the year.
- Regulatory Status: The company is not an emerging growth company. Its common stock trades on The Nasdaq Capital Market under the symbol COCP.
Guidance, Outlook, and Risks
Management commentary indicates a commitment to meeting development milestones despite the quarantine challenges posed by the pandemic. The filing notes that the information regarding financial results is furnished and not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor is it incorporated by reference into other filings unless expressly stated. No specific forward-looking financial guidance or numerical outlook is provided in this text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 30, 2020) for specific revenue, net loss, and cash position figures for the year ended December 31, 2019.
- Consult the Form 10-K filed on March 27, 2020, for comprehensive financial statements and risk factors, as this 8-K only supplements specific operational updates.
- Monitor the company's ability to maintain development timelines given the hybrid remote/essential worker operational model.
- Verify the status of the Bothell research laboratory and any potential future restrictions on "essential" biotechnology operations in Washington State.